Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (577)	4/27/2001 6:49:42 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1784

>> It seems important to follow the industry bellweathers. I consider these to be ABI, IVGN, SIAL, WAT, maybe QGENF. << Agreed. I'd also say perhaps TECH, but they don't seem to be as aggressive. Also, haven't looked in a couple of years, so..... may be far off base. IVGN..... it's been done about as well as it could be done, but I still remember the days in SD when we were whipping their butts (as was Stratagene). >> Sees "on the fringe" new growth coming from ADME-Tox in drug discovery << I remember that the "old Trickle" had KDUS in it, due to the Axiom component. They can't change that tacky website fast enough, but it's got an ADMET component to it now and the old instrumentation focus is gone. The second part is weird, given the Biacore deal. And, to make sure that this post truly has no focus whatsoever, that brings us to......... Friday April 27, 4:55 am Eastern Time Press Release Biacore Awarded Damages in Patent Dispute Estimated Amount: USD 1.7 Million UPPSALA, Sweden--(BUSINESS WIRE)--April 27, 2001-- Biacore International AB (Nasdaq:BCOR - news) Biacore International AB (Biacore) (SSE:BCOR.)(Nasdaq:BCOR - news) today announced that, on April 23, 2001, the U.S. District Court for the District of Delaware granted a permanent injunction preventing Thermo Bioanalysis Corp (Thermo) from infringing Biacore's patent (U.S. patent no. 5,436,161). Furthermore, the Court awarded damages in favor of Biacore AB and Biacore Inc. to be calculated based upon a royalty rate of 40% of the sales price of each IAsys biosensor sold by Thermo since July 25, 1995, plus interest. Although the final amount due to Biacore has not been determined at this time, it is estimated to be in the region of USD 1.7 million. The decision of the Court can be appealed to the Court of Appeals for the Federal Circuit, the centralized appellate Court for patent appeals in the United States. Background On December 30, 1999, the U.S. District Court for the District of Delaware announced its decision in the patent dispute between Biacore and Thermo. The Court decided in Biacore's favor, holding that Biacore's patent was valid and that the patent had been infringed by Thermo's Affinity Sensors unit. The Court further indicated that it ``would grant a permanent injunction preventing Thermo from infringing the '161 patent''' and requested further briefing regarding the amount of damages to be paid by Thermo for its past infringement and concerning the language of the permanent injunction. The Court's April 23, 2001 Judgment addressed these outstanding issues. Biacore is a global market leader in Surface Plasmon Resonance (SPR) based technology with its own sales operations in the U.S., across Europe, in Japan, Australia and New Zealand. The technology is protected by a strong patent portfolio. Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world. Biacore focuses on drug discovery as the prime area for future growth. The company currently has six systems on the market with its BIACORE®3000 system offering specific application in drug discovery processes upstream of high-throughput screening (HTS). A new high-performance system is currently under late- stage development and will focus on applications downstream of HTS. Based in Uppsala, Sweden, the company is listed on the Stockholm Stock Exchange and Nasdaq in the U.S. In 2000 the company has sales of SEK 438.8 million and an operating income of SEK 78.0 million. Further information on Biacore can be found on the web: www.biacore.com This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. This information was brought to you by BIT bit.se The following files are available for download: bit.se bit.se Contact: Biacore International AB Dr. Ulf Jonsson, +46 (0) 18 67 57 00